BCAX logo

BICARA THERAPEUTICS INC

BCAXNASDAQ
🏆 #2336 by market capEarnings Nov 9US Equity
$18.53▼ $0.26 (−1.38%)
After hours · at close
🔔
Track BCAX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.4%
7d▼ 18.7%
14d▼ 18.3%
30d▼ 20.9%
ytd▲ 10.2%
1y▲ 33.5%
🏦Market Cap
$1.22B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
76
Good

Trading Snapshot

Day Range
$18.33 – $18.69
52-Week Range
$13.59 – $30.99
Volume
$2.24B
Avg Volume
$1.57B
Shares Outstanding
65.7M
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$119M
Last Q Revenue
$30M
P/E Ratio
-6.0
P/S Ratio
0.0x
EPS (TTM)
$-2.73
Dividend Yield
0.00%
Dilution (1yr)
+1.3%

Why Investors Own BCAX

  • ✓High-growth profile — revenue up +7.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 68% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BCAX logo

BICARA THERAPEUTICS INC

BCAX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$156M▲ +88.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$107M▲ +43.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
55.1M▲ +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$95M▼ −$394M YoY
StockOtter · stockotter.space

About BICARA THERAPEUTICS INC

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Ratings

ⓘ
Consensus
Buy
22 analysts
Strong Buy7
Buy11
Hold4
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

BICARA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift BCAX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

BICARA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.